Fatima Laher to Adjuvants, Immunologic
This is a "connection" page, showing publications Fatima Laher has written about Adjuvants, Immunologic.
Connection Strength
0,524
-
Protein Dose-Sparing Effect of AS01B Adjuvant in a Randomized Preventive HIV Vaccine Trial of ALVAC-HIV (vCP2438) and Adjuvanted Bivalent Subtype C gp120. J Infect Dis. 2024 Aug 16; 230(2):e405-e415.
Score: 0,239
-
Vaccine Efficacy of ALVAC-HIV and Bivalent Subtype C gp120-MF59 in Adults. N Engl J Med. 2021 03 25; 384(12):1089-1100.
Score: 0,189
-
Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine prime plus bivalent subtype C gp120 vaccine boost adjuvanted with MF59 or alum in healthy adults without HIV (HVTN 107): A phase 1/2a randomized trial. PLoS Med. 2024 Mar; 21(3):e1004360.
Score: 0,058
-
Subtype C ALVAC-HIV and bivalent subtype C gp120/MF59 HIV-1 vaccine in low-risk, HIV-uninfected, South African adults: a phase 1/2 trial. Lancet HIV. 2018 07; 5(7):e366-e378.
Score: 0,039